What is the primary reason for this 8-K filing?

This 8-K filing primarily announces significant leadership changes at Boston Scientific, including the appointment of a new President, an interim CEO, and the retirement of the current President and CEO. It also details the compensation and terms associated with these transitions and updates the company's bylaws.

Who is Michael F. Mahoney and what is his expected role?

Michael F. Mahoney has been appointed President of Boston Scientific, effective October 17, 2011. He has a background in leadership roles at Johnson & Johnson and Global Healthcare Exchange. He is expected to transition into the role of President and Chief Executive Officer by November 1, 2012.

What are the key compensation elements for Michael F. Mahoney?

Mr. Mahoney's compensation includes a $1.5 million sign-on bonus, an additional $750,000 bonus upon promotion to CEO, an annual base salary of $900,000, participation in the Performance Incentive Plan with a target of 120% of base salary, and significant equity awards valued at approximately $9.5 million upon hire and $7.2 million in 2012. He also receives relocation benefits and personal use of corporate aircraft.

What is the company's strategy behind separating the President and CEO roles?

The company has amended its bylaws to formally separate the roles of President and Chief Executive Officer. This structural change allows for a clearer division of responsibilities during the leadership transition and potentially for future operational efficiency, with Mr. Mahoney initially serving as President reporting to the CEO, and eventually holding both roles.

BSX 8-K: Leadership Changes & Corporate Changes

Summary

Boston Scientific Corporation (BSX) has announced significant leadership changes effective October 17, 2011. Michael F. Mahoney has been appointed President, with a clear path to become President and CEO by November 1, 2012. Mahoney brings extensive experience from Johnson & Johnson and Global Healthcare Exchange, with a strong background in medical devices and healthcare solutions. Concurrently, William H. Kucheman will transition from his role as Group President to serve as Interim Chief Executive Officer until Mahoney assumes the CEO position. These leadership transitions coincide with the retirement of J. Raymond Elliott as President and CEO, who will remain on the Board of Directors and serve as a senior advisor through December 31, 2011. The company has also updated its bylaws to formally separate the roles of President and CEO. These changes are aimed at ensuring a smooth leadership transition and positioning the company for future growth.

Key Highlights

1Appointment of Michael F. Mahoney as President, effective October 17, 2011, with a planned promotion to President and CEO by November 1, 2012.
2William H. Kucheman appointed Interim Chief Executive Officer, effective October 17, 2011, until Mahoney assumes the CEO role.
3J. Raymond Elliott retires as President and CEO effective October 17, 2011, and will serve as a senior advisor and remain on the Board of Directors.
4Mahoney's compensation package includes significant bonuses, a base salary of $900,000, and substantial equity awards (DSUs, stock options, PSUs) totaling over $16.7 million.
5Kucheman will receive an annual base salary of $900,000 and an equity award valued at $3 million.
6Elliott will receive an annualized base salary of $856,000 as Senior Advisor and a prorated incentive award.
7Boston Scientific's Bylaws have been amended to formally separate the roles of President and Chief Executive Officer.

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Sep 19, 2011)

Summary

Key Highlights

Frequently Asked Questions